Thematic Exposure -- 8.5/10
Novo Nordisk is the co-dominant player in the most powerful secular growth theme in healthcare:
GLP-1 therapies for obesity and diabetes. Together with Eli Lilly, Novo controls virtually all of
the global GLP-1 market -- a two-player oligopoly in a category with a TAM projected to exceed
$200B by 2030 (>30% CAGR). Novo holds ~62% GLP-1 volume share in international operations and
~54% U.S. diabetes prescription share. Obesity and diabetes represent generational mega-themes
with decades of penetration runway. However, share erosion toward Lilly and the CagriSema pipeline
setback temper the score.
Weight: 25%
Segment Revenue (DKK Millions, Annual)
| Segment | 2020FY | 2021FY | 2022FY | 2023FY | 2024FY | 2025FY | % of 2025 |
|---|---|---|---|---|---|---|---|
| Diabetes and Obesity Care | 108,020 | 121,597 | 156,412 | 215,098 | 271,764 | 289,456 | 93.7% |
| Rare Disease | 18,926 | 19,203 | 20,542 | 17,163 | 18,639 | 19,608 | 6.3% |
Diabetes and Obesity Care dominates at 93.7% of total revenue. Rare Disease (hemophilia, growth
disorders) is a small, stable contributor with no dominant market position.
Key Product Revenue (DKK Millions)
| Product | 2022FY | 2023FY | 2024FY | 2025FY | YoY Growth |
|---|---|---|---|---|---|
| Ozempic (GLP-1 Diabetes) | 59,750 | 95,718 | 120,342 | 127,089 | +5.6% |
| Wegovy (Obesity) | 6,188 | 31,343 | 58,206 | 79,106 | +35.9% |
| Total Obesity | 16,864 | 41,632 | 65,146 | 82,347 | +26.4% |
| Total GLP-1 (Diabetes) | 83,371 | 123,132 | 149,125 | 152,202 | +2.1% |
| Total Diabetes Care | 139,548 | 173,466 | 206,618 | 207,109 | +0.2% |
Wegovy remains the fastest-growing franchise at +35.9% YoY. Ozempic growth has decelerated
sharply from triple-digit rates to +5.6%, reflecting competitive pressure from tirzepatide and
pricing headwinds. Total Diabetes Care was essentially flat in 2025FY.
GLP-1 Duopoly -- Two Players Control the Market
Novo + Lilly = Virtually All of Global GLP-1 Revenue
The GLP-1 market is a textbook two-player oligopoly. Novo Nordisk (semaglutide) and Eli Lilly
(tirzepatide) collectively control virtually 100% of the global GLP-1 market. Barriers to entry
are enormous -- regulatory approval timelines, manufacturing complexity for injectable biologics,
and massive clinical trial investment create a multi-year, multi-billion-dollar moat. No third
player has meaningful market share today, and the earliest potential entrants (Amgen, Pfizer,
Viking Therapeutics) remain in clinical-stage development.
NVO GLP-1 Volume Share (IO)
~62%
International Operations volume
NVO U.S. Diabetes TRx Share
~54%
Total prescriptions, U.S. market
Semaglutide GLP-1 Compound Share
~49%
By active compound, 2024
Lilly GLP-1 Share Trend
Rising to 57%
Q2 2025, up from ~35% in 2023
Market Share and TAM Analysis
| Theme | % of Rev | NVO Market Share | TAM (2025) | Theme CAGR | Oligopoly? |
|---|---|---|---|---|---|
| GLP-1 Diabetes (Global) | ~49% | ~54% US TRx, ~67% IO volume | ~$53B | 12-15% | Yes (NVO + LLY) |
| Obesity / Weight Mgmt (Global) | ~27% | ~43% global (from ~65% in 2023) | ~$25-30B | 30%+ | Yes (NVO + LLY) |
| Insulin (Global) | ~12% | ~28% global value | ~$35B | 2-3% | Oligopoly (NVO, LLY, Sanofi) |
| Rare Disease | ~6% | Niche positions | ~$15B | 5-7% | No dominant position |
Combined GLP-1 diabetes + obesity TAM is projected to exceed $200B by 2030, growing at >30% CAGR.
Obesity alone could reach $130B+ by 2035 per multiple industry sources. NVO exceeds the 30% market
share threshold in both GLP-1 diabetes and obesity -- oligopoly gate passed.
Obesity and Diabetes as Secular Mega-Themes
TAM: $200B+ by 2030 -- >30% CAGR -- Decades of Penetration Runway
Obesity and type 2 diabetes are among the most durable secular growth themes in all of healthcare.
Over 1 billion people globally are classified as obese, and ~500 million live with diabetes. GLP-1
therapies have fundamentally changed the treatment paradigm, moving from chronic disease management
to disease resolution. Current GLP-1 penetration of the addressable obese population remains in
low single digits, implying decades of volume growth even before accounting for expanding
indications (cardiovascular risk reduction, NASH/MASH, sleep apnea, kidney disease). Medicare
Part D coverage for obesity starting mid-2026 could unlock tens of millions of additional patients
in the U.S. alone.
Global Obese Population
>1 Billion
And growing, per WHO
GLP-1 Penetration
Low Single Digits %
Massive runway remains
Obesity TAM by 2035
$130B+
From ~$25-30B in 2025
Medicare Part D Coverage
Mid-2026
Major patient volume catalyst
CagriSema Pipeline Setback -- Risk to Next-Gen Positioning
REDEFINE 4 Failed Non-Inferiority vs Tirzepatide on Weight Loss
CagriSema (semaglutide + cagrilintide) was positioned as the next-generation anchor for the
obesity franchise. The REDEFINE 1 trial delivered ~22.7% weight loss -- below the targeted 25%
threshold management had guided to. More critically, REDEFINE 4 failed to demonstrate
non-inferiority versus tirzepatide (Lilly) on the primary weight loss endpoint. This setback
meaningfully weakens the competitive narrative for the next product cycle. CagriSema FDA filing
has proceeded and a decision is expected by turn of year 2026/2027, but the competitive
positioning against tirzepatide is now structurally disadvantaged. Zenagamtide (amycretin), a
Phase III oral candidate showing 22% weight loss at 36 weeks, represents a potential recovery
option but is years from commercialization.
| Pipeline Event | Outcome / Status | Implication |
|---|---|---|
| REDEFINE 1 (CagriSema) | ~22.7% weight loss (missed 25% target) | Below expectations but still viable |
| REDEFINE 4 (CagriSema vs Tirzepatide) | Failed non-inferiority | Cannot claim parity with Lilly on weight loss |
| CagriSema FDA Decision | Expected turn of year 2026/2027 | Still viable in T2D; weakened in obesity |
| Semaglutide 7.2mg (Higher Dose) | Approval expected Q1 2026 | >20% weight loss -- bridges gap near-term |
| Zenagamtide (Amycretin) Phase III | AMAZE program starting Q1 2026 | 22% at 36 weeks in Phase 1b; years from market |
Competitive Share Erosion
While the two-player oligopoly structure remains intact, the balance of power is shifting toward
Lilly. Novo held ~65% of the global obesity market in 2023 but this has declined to ~43% by 2025
as tirzepatide gained share. In the U.S. GLP-1 market, Lilly reached 57% share by Q2 2025 versus
roughly 35% two years earlier. Ozempic growth has decelerated from triple-digit rates to just
+5.6% in 2025FY. NVO is the weakening #2 in GLP-1, not the strengthening #1. The thematic
tailwind is excellent, but the company-specific competitive trajectory is deteriorating.
Score Rationale
8.5/10 — This is the highest
dimension score for NVO because the underlying thematic is exceptional despite company-specific
headwinds. Novo Nordisk operates at the center of the most powerful secular growth story in
healthcare: GLP-1 therapies for obesity and diabetes, a combined TAM exceeding $200B by 2030 with
>30% CAGR. The two-player oligopoly with Eli Lilly provides structural barriers to entry that
should persist for years. Novo holds ~62% international GLP-1 volume share and ~54% U.S. diabetes
TRx share, well above the 30% oligopoly threshold.
The score does not reach 9 or 10 because: (a) NVO is losing share to Lilly -- global obesity market share has declined from ~65% to ~43% in two years, and Lilly now holds 57% of U.S. GLP-1; (b) the CagriSema pipeline setback (REDEFINE 4 failure vs tirzepatide) weakens the next-generation competitive narrative; (c) Ozempic growth has decelerated to just +5.6%, suggesting the core diabetes franchise is maturing; and (d) pricing destruction from MFN, Medicare Part D, and self-pay channels compresses the revenue realization of the thematic tailwind. The thematic is excellent -- but Novo is increasingly the #2 beneficiary rather than #1.
The score does not reach 9 or 10 because: (a) NVO is losing share to Lilly -- global obesity market share has declined from ~65% to ~43% in two years, and Lilly now holds 57% of U.S. GLP-1; (b) the CagriSema pipeline setback (REDEFINE 4 failure vs tirzepatide) weakens the next-generation competitive narrative; (c) Ozempic growth has decelerated to just +5.6%, suggesting the core diabetes franchise is maturing; and (d) pricing destruction from MFN, Medicare Part D, and self-pay channels compresses the revenue realization of the thematic tailwind. The thematic is excellent -- but Novo is increasingly the #2 beneficiary rather than #1.
Data sourced from Daloopa, company filings, PharmaVoice, Towards Healthcare, and Grand View Research.